Pharma BD Deal Intelligence
Daiichi Sankyo's $200M acquisition of Zepharma successfully built Japan's #3 OTC franchise around cold remedy, digestive, and dermatological brands, growing to ¥86.7B in revenue. But two decades later Daiichi Sankyo reversed course, selling the entire OTC unit to Suntory for ¥246.5B to refocus on its oncology and ADC pipeline.
Zepharma was successfully folded into a scaled OTC franchise, but two decades later Daiichi Sankyo decided consumer health wasn't its future and sold the whole thing to Suntory.
Full analysis, sources & comparables →Astellas sold profitable but sub-scale OTC unit Zepharma to Daiichi Sankyo for ~JPY 23.5B; expected ~JPY 20B extraordinary profit and a refocusing on…
Daiichi Sankyo acquired Zepharma for 23.5 billion yen on April 13, 2006; integration with Daiichi Sankyo Healthcare in April 2007 created Japan's third-largest…
Deal valued at ~$200M; Daiichi Sankyo gains scale in Japanese OTC consumer healthcare, narrowing the gap with Taisho and Takeda category leaders.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
OTC unit divested by Astellas; JPY 23.5B
Zepharma was successfully folded into a scaled OTC franchise, but two decades later Daiichi Sankyo decided consumer health wasn't its future and sold the whole thing to Suntory.
Assessment window: 15yr post-close.
Japanese OTC (over-the-counter) consumer healthcare covers self-medication products — analgesics, gastrointestinal remedies, cold preparations, topical antiseptics — sold without prescription. The market is highly concentrated and dominated by long-established consumer brands; scale is essential to compete with category leaders like Taisho and Takeda Consumer Healthcare.
In Japan's OTC market circa 2006, Taisho Pharmaceutical (Lipovitan, Pabron) and Takeda Pharmaceutical's consumer healthcare unit (Alinamin, Benza) led by a wide margin, with Daiichi Pharmaceutical Healthcare and Sato Pharmaceutical also well established. Astellas's Zepharma — formed at the Yamanouchi/Fujisawa merger in 2005 — marketed Gaster 10 (famotidine OTC, the first switch from Rx H2-blocker in Japan), Cakonal, and Precol cold remedies, and Makiron disinfectant. Astellas determined Zepharma was operationally profitable but sub-scale to compete with category leaders, and chose to divest and concentrate on prescription drugs. Daiichi Sankyo paid JPY 23.5B (~$200M) and merged Zepharma with Daiichi Sankyo Healthcare in April 2007, creating the third-largest Japanese OTC company by sales. The deal was a textbook focus/scale trade — Astellas exits a non-core consumer business, Daiichi Sankyo achieves consumer scale to defend share against Taisho and Takeda.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Daiichi Sankyo Company, Limited / Zepharma Inc. (this deal) | 2006 | $200M | 57 |
| Daiichi Sankyo Company, Limited / Ambit Biosciences | 2006 | $410M | 62 |
| Daiichi Sankyo Company, Limited / Plexxikon Inc. | 2011 | $935M | 51 |
| Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited | 2008 | $4.6B | 14 |
| Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. | 2025 | — | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |